Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

Share Price is delayed by 15 minutes
Get Live Data
336.50    -1.00 (-0.30%)
Bid:
336.50
Ask:
337.00
Spread: 0.50 (0.149%)
Market Cap: £776.20m
CSN Live PriceLast checked at - London Stock Exchange

Intraday Chesnara Share Chart

£150 MILLION RESTRICTED TIER 1 BOND ISSUE

30 Jul 2025 07:00

RNS Number : 0487T
Chesnara PLC
30 July 2025
 

 

LEI Number: 213800VFRMBRTSZ3SJ06

 

 

30 July 2025

 

THIS ANNOUNCEMENT MAY NOT BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, OR TO OR FOR THE BENEFIT OF U.S. PERSONS OR INTO ANY OTHER JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO.

CHESNARA plc

("Chesnara", "the Company" or the "Group")

 

SUCCESSFUL PRICING OF £150 MILLION FIXED RATE RESET PERPETUAL RESTRICTED TIER 1 CONTINGENT CONVERTIBLE NOTES

 

 

Chesnara plc (CSN.L) today announces the successful pricing of £150 million Fixed Rate Reset Perpetual Restricted Tier 1 Contingent Convertible Notes (the "Notes"). The Notes will be issued on 1 August 2025, subject to satisfaction of customary conditions precedent. The net proceeds of the issue of the Notes are expected to be used by Chesnara for its general corporate purposes, including investments and acquisitions.

 

The Notes are expected to be admitted to the Official List of Euronext Dublin and to trading on the Global Exchange Market of Euronext Dublin and are expected to be assigned a rating of BBB- by Fitch Ratings Limited with a stable outlook. The Notes will have an initial coupon of 8.5 per cent. to (but excluding) the first reset date, with the earliest date for redemption of the Notes being 1 August 2030.

 

Steve Murray, CEO of Chesnara, said:

"At the time of the announcement of our proposed acquisition of HSBC Life (UK), we stated that we continued to actively assess ways to optimise our financing options, including the issuance of Restricted Tier 1 instruments. Following the success of our recent £140 million Rights Issue as part of the financing package for the HSBC Life (UK) transaction, we are delighted with the continued support from investors as we seek to ensure we maintain financial flexibility to pursue future acquisitions. We continue to see a positive pipeline of M&A opportunities."

 

 

 

For further information, please contact:

 

Investor Enquiries

Sam Perowne

Head of Strategic Development & Investor Relations

Chesnara plc

E - sam.perowne@chesnara.co.uk

 

Media Enquiries

Misha Bayliss - +44 20 7427 5465

Oscar Burnett - +44 20 7427 5435

Teneo

E - chesnara@teneo.com

 

 

Notes to Editors

Chesnara (CSN.L) is a European life and pensions consolidator listed on the London Stock Exchange. It administers just under one million policies and operates as Countrywide Assured in the UK, as Scildon in the Netherlands and as Movestic in Sweden.

 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in the UK, Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 20 years in succession.

 

Further details are available on the Company's website (www.chesnara.co.uk).

 

IMPORTANT INFORMATION

 

The securities described herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered, sold or delivered within the United States or to or for the account or benefit of U.S. persons, as defined in Regulation S under the Securities Act.

 

This communication is being distributed to and is directed only at persons in the United Kingdom having professional experience in matters relating to investments, falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (the "Order"), and persons falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). In the UK, this communication must not be acted on or relied on by persons who are not relevant persons. In the UK, any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with such persons.

 

MiFID II/UK MiFIR professionals and ECPs-only/No UK/EU PRIIPs KID/FCA CoCo Restriction - the Notes are not intended to be, and must not be, offered, sold or otherwise made available to retail clients (as defined in COBS 3.4) in the UK or to any retail investors in the UK or the European Economic Area (the "EEA"). No key information document (KID) required by Regulation (EU) 1286/2014 or that Regulation as it forms part of UK domestic law has been or will be prepared in respect of the Notes, as the Notes are not available to retail investors in the EEA or the UK.

 

This communication is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful. No action has been taken that would permit an offering of securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

 

Credit ratings referred to in this communication should not be taken as recommendations by a rating agency to buy, sell or hold Notes. They may be revised, suspended or withdrawn at any time by the relevant rating agency.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODSESFLUEISESW
Date   Source Headline
1st Jun 20267:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
29th May 20267:00 amRNSDirector/PDMR Shareholding
27th May 20267:00 amRNSDirector/PDMR Shareholding
19th May 20267:00 amRNSDirector/PDMR Shareholding
14th May 20267:00 amRNSDirector/PDMR Shareholding
12th May 20262:00 pmRNSResult of AGM
1st May 20267:00 amRNSTotal Voting Rights
28th Apr 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSAdmission to Trading
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNSNotice of AGM
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:40 pmRNSDirector/PDMR Shareholding
27th Mar 20267:00 amRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSDirector/PDMR Shareholding
24th Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNSHolding(s) in Company
27th Feb 20267:00 amRNSUpdated Financial Framework and Notice of Results
17th Feb 20267:00 amRNSAcquisition
2nd Feb 20267:00 amRNSCompletion of HSBC Life (UK) Limited Acquisition
30th Jan 20262:00 pmRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
12th Dec 20251:45 pmRNSRegulatory Approval
12th Dec 20257:00 amRNSChange of Registered Office
9th Dec 20257:00 amRNSHolding(s) in Company
2nd Dec 20257:00 amRNSHolding(s) in Company
7th Nov 20257:00 amRNSTotal Voting Rights
30th Oct 20257:00 amRNSHolding(s) in Company
28th Oct 20257:00 amRNSBlock listing Interim Review
27th Oct 202512:04 pmRNSDirector/PDMR Shareholding
6th Oct 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
14th Aug 20257:00 amRNSNotice of Interim Results
13th Aug 20256:00 pmRNSPrimary Health Properties
30th Jul 20257:00 amRNS£150 MILLION RESTRICTED TIER 1 BOND ISSUE
28th Jul 20257:00 amRNSDirector/PDMR Shareholding
23rd Jul 202510:52 amRNSResult of Rump Placing
23rd Jul 20258:15 amRNSDirector/PDMR Shareholding
23rd Jul 20257:00 amRNSAnnouncement re: Rights Issue
8th Jul 20257:00 amRNSAdmission of Nil Paid Rights
3rd Jul 202512:10 pmRNSPublication of a Prospectus
3rd Jul 20257:00 amRNSAcquisition & Rights Issue
1st Jul 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSDirectorate Change
23rd May 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.